Close

Form SC 13G/A Orexigen Therapeutics, Filed by: FMR LLC

May 10, 2016 8:41 AM EDT
SCHEDULE 13G
 
Amendment No. 4
OREXIGEN THERAPEUTICS INC
COMMON STOCK
Cusip #686164104
Check the appropriate box to designate the rule pursuant to which this 
Schedule is filed:
[x] 	  Rule 13d-1(b)
[ ] 	  Rule 13d-1(c)
[ ] 	  Rule 13d-1(d)
Cusip #686164104
Item 1: 	   	Reporting Person - FMR LLC
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	Delaware
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	7,055,902
Item 8: 	   	0
Item 9: 	   	7,055,902
Item 11: 	   	4.806%
Item 12: 	   	HC
Cusip #686164104
Item 1: 	   	Reporting Person - Abigail P. Johnson
Item 2: 	   	(a)  	[ ]
   	   	(b)  	[ ]
Item 4: 	   	United States of America
Item 5: 	   	0
Item 6: 	   	0
Item 7: 	   	7,055,902
Item 8: 	   	0
Item 9: 	   	7,055,902
Item 11: 	   	4.806%
Item 12: 	   	IN
 
Item 1(a). 	    	Name of Issuer:
 
  	  	          	OREXIGEN THERAPEUTICS INC
 
Item 1(b). 	    	Address of Issuer's Principal Executive Offices:
 
  	  	          	3344 N. Torrey Pines Ct.
Suite 200
  	  	          	La Jolla, CA 92037
  	  	          	USA
 
Item 2(a). 	     	 Name of Person Filing:
 
  	   	               	 FMR LLC
 
Item 2(b). 	     	 Address or Principal Business Office or, if None, 
Residence:
 
  	   	               	 245 Summer Street, Boston, Massachusetts 02210
 
Item 2(c). 	     	 Citizenship:
 
  	   	               	 Not applicable
 
Item 2(d). 	     	 Title of Class of Securities:
 
  	   	               	 COMMON STOCK
 
Item 2(e). 	     	 CUSIP Number:
 
  	   	               	 686164104
 
Item 3. 	    	This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) 
or (c) and the
person filing, FMR LLC, is a parent holding company in accordance with
Section 240.13d-1(b)(1)(ii)(G).   (Note:  See Exhibit A).
 
Item 4. 	    	Ownership
 
  	  	     	(a)    Amount Beneficially Owned: 	7,055,902
 
  	  	     	(b)    Percent of Class: 	4.806%
 
  	  	     	(c)    Number of shares as to which such person has:
 
  	  	     	       (i)    sole power to vote or to direct the vote: 	0
 
  	  	     	       (ii)    shared power to vote or to direct the vote: 	0
 
  	  	     	       (iii)    sole power to dispose or to direct the 
disposition of: 	7,055,902
 
  	  	     	       (iv)    shared power to dispose or to direct the 
disposition of: 	0
 
Item 5. 	    	Ownership of Five Percent or Less of a Class.
 
  	    	     	If this statement is being filed to report the fact that as 
of the date hereof, the reporting person has ceased to be the beneficial 
owner of more than five percent of the class of securities, check the 
following (X).
 
Item 6. 	    	Ownership of More than Five Percent on Behalf of Another 
Person.
 
  	 Various persons have the right to receive or the power to direct the 
receipt of dividends from, or the proceeds from the sale of, the COMMON 
STOCK of OREXIGEN THERAPEUTICS INC. No one other person's interest in the 
COMMON STOCK of OREXIGEN THERAPEUTICS INC is more than five percent of the 
total outstanding COMMON STOCK.
  	 
Item 7. 	    	Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent Holding Company.
 
  	    	     	See attached Exhibit A.
 
Item 8. 	    	Identification and Classification of Members of the Group.
 
  	    	     	Not applicable.
 
Item 9. 	    	Notice of Dissolution of Group.
 
  	    	  	Not applicable.
 
Item 10. 	    	Certifications.
 
  	    	     	

By signing below I certify that, to the best of my knowledge and belief, 
the securities referred to above were acquired and are held in the ordinary 
course of business and were not acquired and are not held for the purpose 
of or with the effect of changing or influencing the control of the issuer 
of the securities and were not acquired and are not held in connection with 
or as a participant in any transaction having that purpose or effect.

 
Signature
 
  	    	     	

After reasonable inquiry and to the best of my knowledge and belief, I 
certify that the information set forth in this statement is true, complete 
and correct.

  	May 9, 2016
  	Date
 
  	/s/ Marc R. Bryant
  	Signature
 
  	Marc R. Bryant
  	 Duly authorized under Power of Attorney effective as of September 23, 
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*


* This power of attorney is incorporated herein by reference to Exhibit 24 
to the Form 4 filed by FMR LLC on November 25, 2015, accession number: 
0000315066-15-003312


Exhibit A
 

                 Pursuant to the instructions in Item 7 of Schedule 13G, 
the following table lists the identity and Item 3 classification, if 
applicable, of each relevant entity that beneficially owns shares of the 
security class being reported on this Schedule 13G.

 
Entity 	ITEM 3 Classification
FMR CO., INC 	IA
  	 
  	 

                Abigail P. Johnson is a Director, the Vice Chairman, the 
Chief Executive Officer and the President of FMR LLC.

 

                Members of the Johnson family, including Abigail P. 
Johnson, are the predominant owners, directly or through trusts, of Series 
B voting common shares of FMR LLC, representing 49% of the voting power of 
FMR LLC. The Johnson family group and all other Series B shareholders have 
entered into a shareholders' voting agreement under which all Series B 
voting common shares will be voted in accordance with the majority vote of 
Series B voting common shares. Accordingly, through their ownership of 
voting common shares and the execution of the shareholders' voting 
agreement, members of the Johnson family may be deemed, under the 
Investment Company Act of 1940, to form a controlling group with respect to 
FMR LLC.

 

                Neither FMR LLC nor Abigail P. Johnson has the sole power 
to vote or direct the voting of the shares owned directly by the various 
investment companies registered under the Investment Company Act ("Fidelity 
Funds") advised by Fidelity Management & Research Company ("FMR Co"), a 
wholly owned subsidiary of FMR LLC, which power resides with the Fidelity 
Funds' Boards of Trustees. Fidelity Management & Research Company carries 
out the voting of the shares under written guidelines established by the 
Fidelity Funds' Boards of Trustees.

 

                This filing reflects the securities beneficially owned, or 
that may be deemed to be beneficially owned, by FMR LLC, certain of its 
subsidiaries and affiliates, and other companies (collectively, the "FMR 
Reporters"). This filing does not reflect securities, if any, beneficially 
owned by certain other companies whose beneficial ownership of securities 
is disaggregated from that of the FMR Reporters in accordance with 
Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).

 
RULE 13d-1(k)(1) AGREEMENT
 

                The undersigned persons, on May 9, 2016, agree and consent 
to the joint filing on their behalf of this Schedule 13G in connection with 
their beneficial ownership of the COMMON STOCK of OREXIGEN THERAPEUTICS INC 
at April 29, 2016.

 
  	FMR LLC
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of September 23, 
2015, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
 
  	Abigail P. Johnson
 
  	By /s/ Marc R. Bryant
  	Marc R. Bryant
  	Duly authorized under Power of Attorney effective as of October 12, 
2015, by and on behalf of Abigail P. Johnson*


* This power of attorney is incorporated herein by reference to Exhibit 24 
to the Form 4 filed by FMR LLC on November 25, 2015, accession number: 
0000315066-15-003312

   



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

Fidelity Investments, 13G